Jubiglim M 2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet and exercise alone. Jubiglim M 2 Forte Tablet PR is typically prescribed when monotherapy with either agent is insufficient, offering improved efficacy through complementary mechanisms. It is essential to administer this medication with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Patients should be monitored regularly for glycemic control, renal function, and potential adverse effects including hypoglycemia, lactic acidosis, and vitamin B12 deficiency. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. This medication should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring to achieve optimal therapeutic outcomes.